Bolt Biotherapeutics (NASDAQ:BOLT) Announces Earnings Results

Bolt Biotherapeutics (NASDAQ:BOLT) posted its earnings results on Thursday. The company reported ($2.25) earnings per share for the quarter, beating analysts’ consensus estimates of ($3.68) by $1.43, FiscalAI reports. Bolt Biotherapeutics had a negative return on equity of 126.23% and a negative net margin of 611.47%.

Bolt Biotherapeutics Stock Performance

Shares of Bolt Biotherapeutics stock traded down $0.35 on Thursday, hitting $5.91. 177,672 shares of the company’s stock were exchanged, compared to its average volume of 92,765. Bolt Biotherapeutics has a 1 year low of $3.10 and a 1 year high of $7.78. The company has a 50-day simple moving average of $4.54 and a 200-day simple moving average of $4.52. The company has a debt-to-equity ratio of 1.47, a quick ratio of 2.61 and a current ratio of 2.61. The stock has a market capitalization of $11.41 million, a PE ratio of -0.36 and a beta of 0.85.

Insider Buying and Selling at Bolt Biotherapeutics

In related news, CEO William Quinn sold 9,132 shares of the firm’s stock in a transaction on Friday, September 18th. The stock was sold at an average price of $3.24, for a total value of $29,587.68. Following the transaction, the chief executive officer directly owned 25,384 shares of the company’s stock, valued at approximately $82,244.16. This trade represents a 26.46% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, major shareholder Coastlands Capital Lp bought 50,000 shares of the firm’s stock in a transaction that occurred on Monday, November 9th. The stock was bought at an average cost of $6.38 per share, for a total transaction of $319,000.00. Following the completion of the acquisition, the insider owned 462,416 shares in the company, valued at $2,950,214.08. This trade represents a 12.12% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders sold a total of 38,584 shares of company stock valued at $128,361 over the last 90 days. 9.40% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Bolt Biotherapeutics in a research report on Thursday, October 15th. Two equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Bolt Biotherapeutics has a consensus rating of “Hold” and a consensus target price of $14.50.

Bolt Biotherapeutics Company Profile

Bolt Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on developing treatments that activate the immune system to fight cancer. The company’s approach is designed to combine the targeting capabilities of antibodies with immune-stimulating components that recruit and activate innate immune cells within the tumor microenvironment. Bolt’s proprietary platform centers on Immune-Stimulating Antibody Conjugates, or ISACs. These investigational therapies are intended to bind to specific markers on tumor cells and deliver immune-stimulating payloads, potentially promoting tumor-cell destruction and generating a broader antitumor immune response.